Genzyme Acquires Alfigen, Inc.

Expands its Menu and Service Offerings to Physicians and Patients

24-Feb-2004

Genzyme Genetics, a business unit of Genzyme Corporation, announced that it has purchased substantially all of the assets of Alfigen, Inc., a national genetic testing provider based in Pasadena, California.

This transaction brings together two organizations committed to excellence in genetic testing. The purchase of this privately owned laboratory business allows Genzyme Genetics to expand its extensive test menu and service offerings. Alfigen offers innovative testing technologies and services, such as preimplantation genetic diagnosis, genetic counseling and continuing medical education programming.

"This acquisition provides us with an opportunity to not only leverage Alfigen's twenty years of experience within the industry, but also to utilize our existing assets and bring the combined service offerings to customers of both Alfigen and Genzyme, " says Mara Aspinall, president, Genzyme Genetics. "Like Genzyme, Alfigen's commitment to advancing science is supported by an excellent staff and we are working closely with the Alfigen team to effect a smooth transition. We are eager to continue to provide the highest quality of prenatal, oncology and other testing to physicians and patients."

"I am confident that this combination brings the highest level of quality and service to Alfigen's clients and provides opportunities for growth for Alfigen's employees", says Ahmed Alfi, CEO of Alfigen, Inc.

Genzyme Genetics intends to maintain Alfigen's Pasadena facility, and expects to fully integrate and link its operations with Genzyme's other operations. The terms of the acquisition were not disclosed.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

10+ products
4 whitepaper
10+ brochures
View topic world

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

10+ products
4 whitepaper
10+ brochures